The implication of IP3R in cisplatin resistance was shown by Tsunoda et al. in 2005, where the authors reported a link between the receptor type 1 of IP3R (IP3R1) and increased [Ca2+]i by cisplatin in resistant bladder cancer cell lines [37]. Here, ITPR1 is linked to urinary bladder carcinoma.